| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 12
| Issue : 4 | Page : 168-171 |
|
|
Megestrol acetate in cancer cachexia and anorexia: Tertiary care experience
Kaneez Fatima, Asifa Andleeb, Imtiyaz Hussain, Mushtaq Ahmed Sofi, Afroz Fir, Sumyra Khurshid Qadri
Department of Radiation Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Correspondence Address:
Dr. Kaneez Fatima
Department of Radiation Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jrcr.jrcr_33_21
|
|
|
Background: In clinical practice, the management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge. We conducted an observational study to find the effectiveness and safety of megestrol acetate (MA) for the treatment of CACS. Patients and Methods: One hundred patients of advanced cancer were randomly assigned in the study. Patients received MA 160 mg/oral twice daily. The duration of treatment was 8 weeks. Results: The analysis of the study group demonstrated a statistically significant increase from baseline in body weight (P ≤ 0.01), quality of life (P = 0.02), appetite (P = 0.01), and the Eastern Cooperative Oncology Group performance status (P = 0.03). Conclusion: We concluded that MA is effective and safe in the treatment of CACS.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
![JOURNAL_FULL_NAME]](images/logo.gif){kind=logo}
